多发性硬化症(MS)是一种复杂的慢性,疾病进展导致患者生活质量(QOL)下降,管理式护理组织成本高。目前,疾病修饰治疗(DMT)构成了MS患者的平台药物治疗。尽管它们的功效,对于许多服用DMT的患者,几乎没有证据表明它们对生活质量的影响。流动性受损会造成直接和间接成本。患有步态障碍的MS的年度直接医疗费用平均每位患者近21,000美元。流动性下降也与更高的缺勤率有关,从而提高间接成本。Dalfampridine已被证明可以改善MS患者的步行。dalfampridine的作用可以通过改善步行能力来补充DMT的作用,这是整体活动的关键组成部分,也是许多MS患者的主要关注点。改善步行可能有助于控制与MS护理相关的一些直接和间接成本。
Multiple sclerosis (MS) is a complex chronic, progressing disease that contributes to poor quality of life (QOL) for patients and high costs for managed care organizations. Currently, disease-modifying treatments (DMTs) constitute the platform pharmacotherapy for MS patients. Despite their efficacy, for many patients taking DMTs there is little evidence of their effect on QOL in general or symptom management. Impaired mobility contributes to direct and indirect costs. Annual direct medical costs for MS with gait impairment average nearly $21,000 per patient. Decreased mobility is also associated with higher absenteeism rates, thus raising indirect costs. Dalfampridine has been shown to improve walking in patients with MS. The effects of dalfampridine can complement those of DMTs by improving walking ability as a key component of overall mobility and a primary concern among many MS patients. Improved walking could potentially help contain some of the direct and indirect costs associated with MS care.